María Victoria
Mateos Manteca
Profesora Titular de Universidad
National and Kapodistrian University of Athens
Atenas, GreciaPublicaciones en colaboración con investigadores/as de National and Kapodistrian University of Athens (100)
2024
-
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
Blood Advances, Vol. 8, Núm. 2, pp. 388-398
-
Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting
Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 2, pp. e40-e49.e3
2023
-
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies
Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 9, pp. 687-696
-
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
Blood Advances, Vol. 7, Núm. 14, pp. 3739-3748
-
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials
Blood, Vol. 141, Núm. 6, pp. 579-591
-
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
The Lancet. Oncology, Vol. 24, Núm. 7, pp. e293-e311
-
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269
-
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial
The Lancet Haematology, Vol. 10, Núm. 10, pp. e813-e824
2022
-
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
The Lancet. Haematology, Vol. 9, Núm. 6, pp. e403-e414
-
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
The Lancet Oncology, Vol. 23, Núm. 1, pp. 65-76
-
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781
-
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis (Advances in Therapy, (2022), 39, 5, (1976-1992), 10.1007/s12325-022-02083-8)
Advances in Therapy
-
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322
Annals of oncology : official journal of the European Society for Medical Oncology
-
Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001))
Annals of Oncology
-
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
American Journal of Hematology
-
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
Blood Advances, Vol. 6, Núm. 2, pp. 690-703
-
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial
American Journal of Hematology, Vol. 97, Núm. 4, pp. 481-490
-
Melflufen for the treatment of multiple myeloma
Expert Review of Clinical Pharmacology
-
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
The Lancet Haematology, Vol. 9, Núm. 2, pp. e98-e110
-
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Blood, Vol. 139, Núm. 6, pp. 835-844